<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642550</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-005</org_study_id>
    <nct_id>NCT01642550</nct_id>
  </id_info>
  <brief_title>Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa</brief_title>
  <official_title>A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if administration of RM-131 is effective in
      improving appetite and gastrointestinal symptoms leading to the recovery of patients with
      anorexia nervosa in the outpatient setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of RM-131 on body weight</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-131 on gastric emptying time</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in gastric half-emptying time (t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-131 on appetite</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in appetite.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>RM-131</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active study drug - RM-131</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-131</intervention_name>
    <description>RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.</description>
    <arm_group_label>RM-131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV criteria for anorexia nervosa, including weight &lt;85% of ideal body weight (IBW)
             and amenorrhea for three months;

          -  Age 18-45 years old;

          -  Gastrointestinal tract symptoms;

          -  Non-hormonal method of birth control, which must be used throughout the study. Female
             patients unable to bear children must have this documented (i.e., tubal ligation,
             hysterectomy, or post-menopausal, defined as a minimum of one year since the last
             menstrual period and elevated FSH);

          -  Stable concomitant medications defined as no changes in regimen for at least 2 weeks
             prior to baseline;

          -  Able to provide written informed consent prior to any study procedures and be willing
             and able to comply with study procedures, including daily SC injections and completion
             of a daily injection log.

          -  Patient has a primary care physician or treatment team managing her care.

        Exclusion Criteria:

          -  Use of hormone therapy (including but not limited to estrogen, progesterone) or
             hormonal methods of birth control (i.e., oral, implantable, or injectable) within
             eight weeks of screening; or Depo-Provera within six months of screening;

          -  Pregnancy, lactation or breastfeeding, or a positive serum or urine pregnancy test,
             within eight weeks of screening;

          -  History of diabetes mellitus;

          -  History of purging behaviors greater than once monthly within the last three months;

          -  Active substance abuse;

          -  Use of metoclopramide, erythromycin, 5HT3 anti-emetics, or opioid medications within 2
             weeks prior to baseline. [Note: these drugs should also not be used post-baseline];

          -  Hematocrit &lt; 30.0 %, hemoglobin &lt; 10.0 g/dl, potassium &lt; 3.0 mmol/L, fasting glucose &gt;
             100 mg/dL, creatinine &gt; 1.5 mg/dL, AST or ALT &gt; 1.5 times the upper limit of normal,
             or abnormal plasma thyroid stimulating hormone (TSH) level;

          -  Currently receiving parenteral feeding or enteral feeding, or presence of a
             nasogastric or other enteral tube for feeding or decompression;

          -  History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker
             placement, vagotomy, bariatric procedure, small or large bowel resection;

          -  Clinical suspicion, in the opinion of the investigator, of active or symptomatic
             peptic ulcer disease, cholelithiasis, colitis, celiac sprue, or inflammatory bowel
             disease;

          -  Active suicidal ideation;

          -  Beck Depression Inventory-2 score of â‰¥ 29;

          -  Current inpatient hospitalization;

          -  Allergic or intolerant of egg, milk, wheat or algae, as these are components of the
             GEBT test meal;

          -  Participation in a clinical study with an investigational medication or device within
             the 30 days prior to dosing in the present study;

          -  Any other reason, which in the opinion of the Investigator, including severe renal,
             hepatic or cardiac disease, would confound proper interpretation of the study or
             expose a patient to unacceptable risk.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Klibanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <disposition_first_submitted>December 2, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 2, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 1, 2016</disposition_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anorexia nervosa</keyword>
  <keyword>Anorexia</keyword>
  <keyword>Eating disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

